Abstract library

8 results for "Valls".
#1644 Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: PPRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic GEPNETs
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Tessa Brabander
#729 Neuroendocrine Neoplasms of the Ampulla of Vater: Clinicopathological Analysis of Nine Cases
Introduction: Neuroendocrine neoplasms (NEN) of the ampulla of Vater (AV) are rare and heterogeneous and little is known about their biological behavior.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Luis Perez-Casanova
#971 Well-differentiated Pancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
Introduction: Well-differentiated (WD) pancreatic neuroendocrine tumors (pNET) are uncommon neoplasms and one challenge lies in predicting tumor behavior and managing these patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Luis Pérez-Casanova
#975 Electron Microscopy of Pancreatic Beta Cell Neuroendocrine Tumors (NETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mice Reveal an Adenomatous Phenotype with Depletion of Insulin Granules and Increased Mitochondrial Content
Introduction: Insulinomas are β cell neuroendocrine tumors (NETs) that secrete insulin, and ~4% of insulinoma patients have multiple endocrine neoplasia type 1 (MEN1). One in ten MEN1 patients present with an insulinoma. Previous reports describe insulinomas as possibly having typical granules (46.4%) or atypical smaller granules (34.3%), both associated with adenomas, or agranular cells (14.3%) associated with carcinomas. MEN1 knockout (Men1+/-) mice develop pancreatic NETs that are mostly insulinomas, and their ultrastructural phenotype is unknown. We hypothesized that these may resemble the adenoma phenotype with atypical granules.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Gerard V Walls
Authors: Walls G V, Clark A, Thakker R, ...
Keywords: GEP-NET
#1394 The Difficulties of Response Assessment After Peptide Receptor Radionucleotide Therapy (PRRT): An Unusual Case of Symptomatic Pseudoprogression
Introduction: In previous studies patient symptoms, biochemistry (including chromogranin A) and imaging using RECIST criteria have been used to assess tumour response to PRRT.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Lyle M, Wyld D, Burge M, ...
#1741 Complete Remission of Hepatic Metastasis after Total Gastrectomy for a Gastric Carcinoid Tumor Type 1: A Case Report
Introduction: A 58-year-old woman was referred to our hospital for hepatic lesions and thickening of the walls of the stomach detected by abdominal CT scan. An upper GI endoscopy showed a lesion of the body of the stomach and the histopathologic exam documented a well differentiated NET. 68Ga-DOTATOC PET showed pathologic uptake in the stomach and in the liver (3 lesions). Circulating chromogranin A and gastrin were 596 ng/ml and 2283 pg/ml respectively
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Valeria Smiroldo
#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis
#2263 Patient Survey Devoted to Characterizing Experience and Expectations of Patients with Neuroendocrine Tumors (NET)
Introduction: Patients (pts) with NET experience consequences of disease progression and treatments; their preferences can influence the choice and success of therapeutic strategies.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Matthieu Sarabi
Authors: Sarabi M, Gueguen D, Walter T, Hentic O, ...